Compare · LLY vs NRIX
LLY vs NRIX
Side-by-side comparison of Eli Lilly and Company (LLY) and Nurix Therapeutics Inc. (NRIX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LLY and NRIX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LLY is the larger of the two at $1.16T, about 415.2x NRIX ($2.80B).
- Over the past year, LLY is up 67.6% and NRIX is up 182.7% - NRIX leads by 115.1 points.
- LLY has been more active in the news (17 items in the past 4 weeks vs 9 for NRIX).
- LLY has more recent analyst coverage (25 ratings vs 20 for NRIX).
- Company
- Eli Lilly and Company
- Nurix Therapeutics Inc.
- Price
- -
- -
- Market cap
- $1.16T
- $2.80B
- 1M return
- +3.00%
- +15.16%
- 1Y return
- +67.64%
- +182.75%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2020
- News (4w)
- 17
- 9
- Recent ratings
- 25
- 20
Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Nurix Therapeutics Inc.
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader with immunomodulatory drug (IMiD) activity for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader without IMiD activity for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It also develops NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy; DeTIL-0255 for tumor infiltrating lymphocytes therapy; KINASE-CTM3 to treat T cell malignancies and autoimmune diseases; and LIGASE-INH2 for immuno-oncology. In addition, the company develops programs, such as COVID-CTM1, COVID-CTM2, and COVID-CTM3 that are designed for protein degradation to SARs CoV2 targets. Nurix Therapeutics, Inc. has a strategic collaboration agreement with Gilead Sciences, Inc. for cancer and other challenging diseases patients; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.
Latest LLY
- Zepbound linked to lower healthcare costs in adults over age 55 with obesity according to a real-world study
- Most AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does.
- Director Sulzberger Gabrielle was granted 4 shares, increasing direct ownership by 0.14% to 3,004 units (SEC Form 4)
- Director Luciano Juan R was granted 13 shares, increasing direct ownership by 0.08% to 16,918 units (SEC Form 4)
- Director Fyrwald J Erik was granted 8 shares, increasing direct ownership by 0.01% to 75,418 units (SEC Form 4)
- Director Alvarez Ralph was granted 10 shares, increasing direct ownership by 0.02% to 55,745 units (SEC Form 4)
- EVP & President, LLY Int'l Jonsson Patrik sold $7,638,150 worth of shares (6,500 units at $1,175.10) as part of a pre-agreed trading plan, decreasing direct ownership by 11% to 54,147 units (SEC Form 4)
- A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
- The GLP-1 Boom Created a Tissue Gap Fillers Were Not Built For
- Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market
Latest NRIX
- Nurix Therapeutics Announces Appointment of Wes Burwell as Chief Human Resources Officer
- Amendment: SEC Form SCHEDULE 13G/A filed by Nurix Therapeutics Inc.
- SEC Form SCHEDULE 13G filed by Nurix Therapeutics Inc.
- Chief Scientific Officer Hansen Gwenn exercised 4,356 shares at a strike of $1.86 and sold $108,900 worth of shares (4,356 units at $25.00) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Scientific Officer Hansen Gwenn sold $100,142 worth of shares (4,111 units at $24.36) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 117,227 units (SEC Form 4)
- Chief Financial Officer Van Houte Hans sold $115,989 worth of shares (4,761 units at $24.36) as part of a pre-agreed trading plan, decreasing direct ownership by 11% to 40,166 units (SEC Form 4)
- Nurix Announces $10 Million Milestone Payment Associated with Initiation of a Phase 1 Clinical Trial of a STAT6 Degrader
- Nurix Therapeutics Announces First Patient Enrolled in Registrational Phase 3 DAYBreak CLL-306 Trial of Bexobrutideg in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Chief Legal Officer Ring Christine exercised 5,787 shares at a strike of $8.72 and sold $382,358 worth of shares (16,589 units at $23.05) as part of a pre-agreed trading plan, decreasing direct ownership by 54% to 9,110 units (SEC Form 4)
- Chief Financial Officer Van Houte Hans converted options into 10,180 shares and sold $66,524 worth of shares (2,845 units at $23.38), increasing direct ownership by 20% to 44,927 units (SEC Form 4) (withholding obligation)